Category Archives: Client News

Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy

NEW YORK, Oct. 17, 2018 — Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received on Tuesday, October 16, Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) … Continue reading


Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy

Narcolepsy is a debilitating, orphan neurological condition with limited treatment options Phase 2 trial set to start in 4Q 2018 with results anticipated in 1H 2019 Conference call and webcast scheduled for today at 8:00 AM Eastern Time NEW YORK, … Continue reading


Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

NEW YORK, Oct. 15, 2018 — Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced the … Continue reading


Motif Bio Presents New Iclaprim Data at IDWeek

Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials NEW YORK, Oct. 03, 2018  — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data are … Continue reading


Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa

NEW YORK, Oct. 01, 2018 — Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, … Continue reading


TG Therapeutics, Inc. to Present at Upcoming Investor Conferences

NEW YORK, Sept. 28, 2018  — TG Therapeutics, Inc. (TGTX) today announced its participation at two upcoming investor conferences.  Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled to present at the following conferences: The Cantor … Continue reading


TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Accepted for Oral Presentation at the Upcoming 34th Congress of ECTRIMS

Annualized Relapse Rate (ARR) of 0.07 observed for all patients Complete (100%) elimination of T1 Gd-enhancing lesions at week 24 and maintained at week 48 NEW YORK, Sept. 26, 2018  — TG Therapeutics, Inc. (TGTX), today announced that the final … Continue reading


ProQR Announces Presentations at the OTS Annual Meeting

LEIDEN, the Netherlands, Sept. 24, 2018  — ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the Oligonucleotide Therapeutics … Continue reading


Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 24, 2018 — Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate … Continue reading


Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

NEW YORK, Sept. 20, 2018  — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti & Company Fall 2018 Investor Conference … Continue reading


Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

NEW YORK, Sept. 20, 2018  — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7, 2018 San Francisco, CA  … Continue reading


AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 19, 2018 — AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections … Continue reading


Eyenovia to Participate in Panel Presentation at OSN New York 2018

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) — Eyenovia, Inc. (EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s … Continue reading


Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference

NEW YORK, Sept. 18, 2018  — Eyenovia, Inc. (EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive … Continue reading


ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018  — ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the closing of … Continue reading


ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018  — ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the closing of … Continue reading


Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

NEW YORK, Sept. 07, 2018 — Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately.  Dr. Olukotun assumes the seat held by Dr. Ernest Mario, who has stepped … Continue reading


AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund

GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics, Inc. (AITB) (“AIT Therapeutics or the “Company”), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients … Continue reading


AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences

Highlights at European Respiratory Society (ERS) to include updated data from company’s NO-BRO Pilot study of high-dose inhaled nitric oxide (NO) in infants hospitalized with acute bronchiolitis              Additional pre-clinical data at ERS and European Society … Continue reading


Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

NEW YORK, Sept. 04, 2018  — Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, … Continue reading